Fundraising Fox
Synkrino Biotherapeutics
YC S18San Francisco, US · 2 employees · 4 known investors
Find your way into Synkrino Biotherapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Sign up to find every way you can get introduced to Synkrino Biotherapeutics
- Your email: who you already know at Synkrino Biotherapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Synkrino Biotherapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Building new drugs to target inflammation using an AI + immunology discovery engine.
Also known as SF17 Therapeutics
Founders & leadership· Y Combinator alumni (S18)
DO
David OttData Scientist, Co-Founder2017–2024He brings expertise in data science and machine learning to the field.
Investors · 4
Blue Bear Ventureslisted by Blue Bear VenturesBerkeley · $100K – $400K
How we know: Blue Bear Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Y Combinatorlisted by Y CombinatorSan Francisco · $500K
How we know: the Y Combinator directory · Not right? Tell us
Fundamental VenturesreportedLakeway
How we know: Y Combinator's founder network · Not right? Tell us
MicroVenturesreportedAustin · $150K – $1M
How we know: Y Combinator's founder network · Not right? Tell us
Related companies · 5
Parallel BioParallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery. The company aims to accelerate pharmaceutical development and reduce clinical trial failure rates through human-first biological prediction models.
Paceline BioPlay Health builds a clinical decision-support platform for healthcare providers to deliver personalized menopause and women's health care. The platform serves primary care physicians and other providers treating women navigating perimenopause and menopause.
Harmonic DiscoveryHarmonic Discovery applies medicinal chemistry, cheminformatics, data science and machine learning expertise to advance drug discovery. The company is supported by investors at the intersection of technology, biology and medicine.
SFA TherapeuticsSFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.
Reverie LabsReverie Labs develops cancer treatments designed to cross the blood-brain barrier and treat tumors in the central nervous system.
Companies working in the same space as Synkrino Biotherapeutics.
Frequently asked questions
- What does Synkrino Biotherapeutics do?
- Building new drugs to target inflammation using an AI + immunology discovery engine.
- Who founded Synkrino Biotherapeutics?
- Synkrino Biotherapeutics was founded by Jason Barbour, David Ott.
- Who are Synkrino Biotherapeutics's investors?
- Synkrino Biotherapeutics's investors include Blue Bear Ventures, Y Combinator, Fundamental Ventures, MicroVentures.
- Where is Synkrino Biotherapeutics headquartered?
- Synkrino Biotherapeutics is headquartered in San Francisco, US.